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Abstract
Introduction: Autosomal dominant polycystic kidney 
disease (ADPKD) is the most common life threatening 
hereditary disease of the kidney. It is a systemic disease 
characterized by multiple, bilateral renal cysts that result 
in massive renal enlargement and progressive functional 
impairment. This review discusses the current understanding 
of the epidemiology, genetics, clinical manifestations, 
natural history of the disease, the accuracy and reliability 
of diagnostic approaches, renal replacement therapy and 
emerging therapeutic strategies that are being evaluated in 
ADPKD.
Review: ADPKD is a genetically heterogeneous disease 
with significant inter-familial and intra-familial variability. 
The responsible genes were localized to separate loci on 
chromosome 16 (PKD1 gene) accounting for the majority of 
ADPKD cases, and chromosome 4 (PKD2 gene) accounting 
for the remainder.  Each child of an affected parent has 
a 50% chance of inheriting the mutated gene, which is 
completely penetrant. Clinical manifestations include renal 
and cyst enlargement, impaired urine concentration capacity, 
hematuria, nephrolithiasis, proteinuria, hypertension, 
polycystic liver disease, abdominal wall hernia and 
intracranial aneurysms. The diagnosis of ADPKD usually 
relies on renal imaging. Ongoing research has engendered 
crucial insight into the disease’s underlying genetic, cellular 
and pathogenetic mechanisms and made possible the design 
and implementation of clinical trials testing promising 
treatments. Renin Angiotensin Aldosterone System (RAAS) 
blockade, vasopressin antagonists, somatostatin, rapamycin, 
sirolimus and everolimus are currently being evaluated for 
a potential therapeutic role in the management of ADPKD. 
Conclusion: Current clinical trials investigating multiple 
therapeutic targets bring hope for treatments that may 
impede the progression of ADPKD. 
keywords: ADPKD, autosomal dominant polycystic 
kidney disease, kidney failure
Introduction
Autosomal dominant polycystic kidney disease (ADPKD) 
is the most common inheritable disorder of the kidney. 
It affects all racial groups worldwide, with a frequency 
of 1:400 to 1:1000 live births [1]. ADPKD is the fourth 
most common cause for end-stage renal disease (ESRD) 
worldwide and accounts for 5–10% of renal transplant 
recipients, making it a major global health care burden 
[1, 2]. It is a systemic disease characterized by multiple, 
bilateral renal cysts that arise typically from nephron 
segments, resulting in massive renal enlargement and 
progressive functional impairment. The onset of the 
disease is bimodal, with most patients presenting in the 
third to fifth decades of life and a clinically significant 
subset of patients presenting in infancy and childhood. 
Typically, only a few renal cysts are detected in most 
affected individuals before 30 years of age. However, 
by the fifth decade of life, numerous renal cysts will 
be found in the majority of patients. Patients with 
established disease can have their enlarged kidneys 
each measure up to 40 cm in length (compared with 
10 to 12 cm in normal kidneys) and weigh up to 8 kg 
(compared with 400 to 500 g in normal kidneys) [3]. The 
degree of kidney enlargement, in turn, correlates with 
complications such as pain, hematuria, hypertension, 
and renal insufficiency. Numerous renal and extra-
renal manifestations have been described for ADPKD. 
The typical adult presentation includes decreased renal 
concentrating ability, hematuria, and flank pain resulting 
from cyst expansion. Hypertension, left ventricular 
hypertrophy (LVH), cardiac valvular defects, back and 
abdominal pain, cerebral aneurysms, and liver cysts are 
the most important clinical findings. 
Genetics
ADPKD is genetically heterogeneous with separate loci 
on chromosome 16 (PKD1), accounting for approximately 
85% of ADPKD cases, and on chromosome 4 (PKD2), 
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accounting for approximately 15% of patients [4].  PKD1 
and PKD2 genes encode plasma membrane–spanning 
proteins polycystin-1 and polycystin-2 respectively 
(Figure 1). The polycystins regulate tubular and vascular 
development in the kidneys and other organs (liver, brain, 
heart, and pancreas) and interact to increase the flow 
of calcium through a cation channel formed in plasma 
membranes by polycystin-2 [5]. 
A mutation of either polycystin can disrupt the function 
of the other, resulting in similar clinical presentations. 
Recently a third gene, PKD3, has been suspected in few 
families but has not yet been identified. Each child of 
an affected parent has a 50% chance of inheriting the 
mutated gene, which is completely penetrant. ADPKD 
arises as a spontaneous mutation in approximately 5% of 
cases. However, in about one fourth of newly diagnosed 
cases, patients report no family history of the disease, 
indicating that many familial cases go undetected. The 
disease has large interfamilial and intrafamilial variability 
in the severity of renal and extrarenal manifestations 
pointing to genetic and environmental modifying factors 
[6]. Mutations on PKD1 gene are likely to be associated 
with more renal cysts, and to lead to renal insufficiency 
on average 20 years earlier (median ages at the time of 
death or end stage renal failure with PKD1 and PKD2 
mutations are  53 and  69 years, respectively) [7, 8]. With 
both PKD1 and PKD2, older patients generally have 
more cysts, indicating that the cystogenesis continues 
throughout the life of patients. 
Figure 1: Structure of polycystin-1 and polycytin-2*  
* Reproduced with permission [9]
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Clinical manifestations
Renal manifestations
Renal and cyst volume enlargement
Kidney enlargement as a result of cyst expansion is 
the hallmark of ADPKD and this directly translates 
into the renal manifestations of the disease. Continued 
enlargement of the cysts often leads to progressive 
renal failure. Other renal manifestations include urinary 
tract infection, urinary concentrating defect, hematuria, 
nephrolithiasis and acute or chronic flank and abdominal 
pain. In comparison with glomerular filtration rate (GFR), 
which deteriorates very slowly in early stages of ADPKD 
and therefore is not a robust marker of disease progression, 
magnetic resonance imaging (MRI) assessment of renal 
volume seems to provide a promising tool for monitoring 
early disease progression and assessing the efficacy of 
therapeutic interventions. A study of 241 early ADPKD 
patients followed up prospectively with yearly MRI 
examinations by the Consortium of Radiologic Imaging 
Studies to assess the Progression of Polycystic kidney 
Disease (CRISP) has provided invaluable insight to 
understand how the cysts develop and grow (Table 1). 
In the CRISP study, Grantham et al demonstrated that 
renal enlargement occurs in a quantifiable, exponential 
manner and can be correlated directly with the decline 
in renal function [7, 10]. Baseline total kidney volume 
predicted the subsequent rate of increase in renal volume 
and was associated with declining GFR in patients with 
baseline total kidney volume above 1500 ml. Kidney and 
cyst volumes consistently increased in both the PKD1 
and PKD2 populations but the absolute rate of change 
was greater in PKD1 (74.9 ml/year) than PKD2 (32.2 ml/
year). However, this was due to the larger baseline sizes 
of the kidneys; the rates of growth for kidney and cyst 
volume were not significantly different (5.68% per year 
for PKD1 vs. 4.82% per year for PKD2). This indicates 
that gene type does not strongly influence the size of 
ADPKD kidneys by modulating the relative rate of cyst 
growth but rather by cyst initiation. Gender, however, 
affected both the absolute and relative rates of kidney and 
cystic expansion in the ADPKD population, with male 
patients showing more rapid expansion.
Concentration impairment
Impaired urinary concentrating capacity is common even 
at early stages [16]. Plasma vasopressin concentrations are 
increased; therefore a central cause has been excluded [17]. 
The underlying mechanism is not known, but disruption 
of tubular architecture, defects in principal cell function, 
or early tubulointerstitial disease are postulated factors. 
Recent studies suggest that the urinary concentrating 
defect and raised vasopressin concentrations could 
contribute to cystogenesis [18]. Defective medullary 
trapping of ammonia and transfer to the urine caused 
by the concentrating defect could contribute to the low 
urine pH values, hypocitric aciduria, and predisposition 
to stone formation [19]. 
Hematuria
Rupture of a cyst into the collecting system is thought 
to be responsible for the development of hematuria. 
Although hemorrhage into a cyst is also common, the 
typical presentation is pain rather than hematuria since 
many cysts do not communicate with the collecting 
system [20].  Hematuria occurs at some time in the course 
of the disease in 42-50% of ADPKD patients and may 
be the initial diagnostic clue [21]. Both kidney size and 
hypertension have direct correlation with the incidence 
of gross hematuria. Nephrolithiasis is another cause of 
hematuria. Hematuria usually resolves within two to 
Table 1: Summary of the Consortium of Renal Imaging Studies in Polycystic Kidney Disease (CRISP) Studies Observations
Liver cyst Disease•	 : 94% prevalence of liver cystic disease by age 35, women affected more often than men [11].
Genotype•	 : PKD1 individuals demonstrate larger kidneys with more cysts than age-matched PKD2 individuals. Rates of change 
in cyst growth are similar between PKD1 and PKD2 individuals [7].
Hypertension•	 : hypertensive ADPKD individuals as compared to age matched normotensive ADPKD individuals demonstrate 
larger kidney volumes that grow at a faster rate [10].
Kidney volume•	 : increases over time with growth due to cyst expansion, associated with proteinuria and reduction in GFR [7].
Renal blood flow•	 : is reduced early in ADPKD, prior to loss of renal function and is associated with increased renal size [12, 13].
Imaging•	 : ultrasound versus MRI imaging demonstrates reduced reliability and reproducibility and decreasing correlations with 
MR-based estimates of renal volume as kidney size increases [14, 15].
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seven days with conservative therapy consisting of bed 
rest and hydration. 
Nephrolithiasis
Kidney stones occur in approximately 20% of patients 
with ADPKD [22]. The composition of the stones 
is most frequently uric acid and/or calcium oxalate. 
Metabolic factors are important in their pathogenesis 
as well as mechanical distortions induced by large 
cysts. As discussed above, aciduria and hypocitruria 
due to abnormal ammonium transportation are the 
most common abnormalities while distal acidification 
defects may be important in a few patients. Unlike other 
cases of nephrolithiasis, it is more difficult to establish 
the diagnosis by ultrasonography in ADPKD patients, 
because of the large cysts and calcifications which 
may be present in the cyst walls. Most stones can be 
detected by intravenous pyelography, but CT scanning is 
more sensitive for the detection of small or radiolucent 
stones [22]. A patient with nephrolithiasis is given the 
same treatment whether or not they have a concurrent 
diagnosis of ADPKD. Extracorporeal shock wave 
lithotripsy (ESWL) and percutaneous nephrolithotomy 
in patients with early disease and normal renal function 
are not contraindicated. 
Proteinuria
Proteinuria is not considered a major feature of ADPKD. 
However, the presence of proteinuria may be an indicator 
of sub-clinical other end-organ damage, including 
left ventricular hypertrophy (LVH) and systemic 
atherosclerosis. Recent studies have shown significant 
association between left ventricular mass index (LVMI) 
and proteinuria [23, 24]. In ADPKD patients, proteinuria 
is considered an important predictor of renal disease 
progression.  In a study of 270 ADPKD patients, only 48 
(18%) of subjects had overt proteinuria (>300 mg per day) 
[25]. Interestingly, all these patients had hypertension 
and large renal volumes. The same group of patients 
had greater renal functional impairment, faster disease 
progression and an increased incidence of hematuria 
[24]. A 5-year prospective, randomized study of 24 
ADPKD patients examined the anti-albuminuric effect of 
amlodipine, a calcium channel blocker, versus enalapril, 
an angiotensin converting enzyme (ACE) inhibitor. 
Albumin to creatinine ratio increased significantly in the 
amlodipine-treated, but was stable in the enalapril-treated 
group at comparable levels of blood pressure (BP) control 
[26]. We can therefore propose that the sustained anti-
albuminuric effect of ACE inhibitors may improve the 
long-term renal and cardiovascular prognosis in ADPKD 
patients.
Hypertension
Hypertension is the most common complication of 
ADPKD, occurring in approximately 60% of patients 
before any significant reduction in glomerular filtration 
rate [27, 28]. Hypertension is diagnosed at a much earlier 
age in ADPKD patients, with a median of 32 years in males 
and 34 years in females [29]. Prevalence of hypertension 
in children with ADPKD is between 5% and 44%, but 
is difficult to ascertain accurately because of selection 
biases and the different definitions of hypertension used 
in different studies [30]. Several studies have shown that 
hypertension in ADPKD is associated with increased 
renal volume and LVMI, in both adults and children. 
Hypertension and LVMI are important risk factors for 
cardiovascular disease, which is the most common cause 
of death in patients with ADPKD [31-33].
There is evidence that early activation of the renin-
angiotensin system is important in the pathogenesis 
of hypertension in ADPKD. Angiographic studies 
have demonstrated that cyst enlargement in ADPKD 
is associated with compression of the adjacent 
parenchyma and vasculature [34, 35].  Several studies 
have indicated increased concentrations of renin in 
both tissue and cyst fluid from ADPKD patients [36]. 
Moreover, further studies have shown an intrarenal 
role of renin angiotensin aldosterone system (RAAS) 
in the pathogenesis of ADPKD. This is indicated by 
detecting the angiotensinogen, angiotensin-converting 
enzyme (ACE), angiotensin II type-1 (AT1) receptor, 
and angiotensin II within cysts and tubules of ADPKD 
kidneys [37]. These results suggest activation of the 
RAAS secondary to renal ischemia. 
Other factors proposed to contribute to hypertension in 
ADPKD include increased sympathetic nerve activity and 
increased plasma endothelin-1 concentrations [38, 39]. 
AT1 is known to stimulate the pro-fibrogenic cytokine, 
transforming growth factor beta. This is an important 
finding as renal interstitial fibrosis is a hallmark of 
ADPKD. Angiotensin II may also have proliferative 
effects on tubular epithelial cells via epidermal growth 
factor (figure 2) [40, 41].
In ADPKD, hypertension often remains undiagnosed until 
late in disease progression. Twenty four hour ambulatory 
BP monitoring of children or young adults without 
hypertension can reveal raised BP, attenuated nocturnal 
blood-pressure dipping and exaggerated blood-pressure 
response during exercise, which can be accompanied 
by LVH and diastolic dysfunction [43]. Hypertension 
and subsequent LVH are important risk factors for 
cardiovascular disease, which is the most common cause 
of death in patients with ADPKD. Uncontrolled BP also 
increases the risk for proteinuria, hematuria, decline of 
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renal function, and morbidity and mortality from valvular 
heart disease and aneurysms. Thus, early detection and 
treatment of hypertension is important [26, 33, 44]. 
Moreover, the presence of hypertension increases the 
risk of pre-eclampsia and fetal loss, while normotensive 
ADPKD women usually have uncomplicated pregnancies 
[45].
Extra-renal manifestations
Polycystic liver disease 
Polycystic liver disease is the most common extrarenal 
manifestation of ADPKD. It is associated with both 
PKD1 and PKD2 genotypes and may also occur as a 
distinct disease in the absence of renal cysts [46, 47]. The 
frequency of hepatic cysts increases with age and may 
have been underestimated by ultrasound and CT studies. 
The prevalence of hepatic cysts detected by MRI in the 
CRISP study was 58% in 15−24 year olds, 85% in 25−34 
year olds, and 94% in 35−46 year old participants [11]. 
Hepatic cysts are more common and larger in volume 
in female than male patients. Women with multiple 
pregnancies or history of oral contraceptives may present 
with more severe disease, suggesting an effect of estrogen 
on hepatic-cyst growth without a significant effect on 
renal volume [48].
Liver cysts arise by excessive proliferation and dilatation 
of biliary ductules and peri-biliary glands. Growth of 
liver cysts is promoted by estrogen receptors which are 
expressed in the epithelial lining of the cysts as well as 
by growth factors and cytokines secreted into the cyst 
fluid [49, 50].
Hepatic cysts are typically asymptomatic but symptoms 
might increase as the life spans of polycystic disease 
Figure 2: Multifactorial pathogenic role of angiotensin II in hypertension and renal disease association with autosomal dominant 
polycystic kidney disease*   
* Reproduced with permission [42]
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patients are prolonged by dialysis and transplantation. 
Liver function tests are usually normal in ADPKD 
patients with liver involvement. Despite the progressive 
nature of the cystic disease, the hepatic parenchyma 
remains normal, both histologically and physiologically 
[51]. Symptoms may arise from mass effects or from 
complications related to the cysts. Mass effects from 
enlarging cysts and hepatomegaly include dyspnea, 
early satiety, gastro-esophageal reflux, mechanical 
low back pain and abdominal hernias. Pain is the most 
disabling complication of polycystic liver disease. Other 
complications are hepatic venous outflow obstruction, 
compression of the inferior vena cava, portal-vein 
compression, or bile-duct compression presenting as 
obstructive jaundice [52].
In asymptomatic patients, no treatment is indicated for 
polycystic liver disease. In the symptomatic patient, 
surgery is the mainstay of treatment tailored to the extent of 
the disease for each patient. Management options include 
cyst aspiration and alcohol sclerosis, open or laparoscopic 
fenestration, liver resection with fenestration, and liver 
transplantation [53]. Acute hepatic cyst complications 
are cyst hemorrhage and infection. Right abdominal pain 
accompanied with fever and leukocytosis in ADPKD 
patients could result either from right kidney or liver 
cyst infection [54]. The incidence of bacteremia is high 
with infected liver cysts and is detected in about 63% of 
cases with positive blood cultures. Common organisms 
are gram-negative bacteria such as E.coli [55]. Infected 
liver cysts should be diagnosed and treated aggressively. 
Blood and/or cyst fluid cultures are necessary. In 
contrast to renal cyst infections, both antibiotic therapy 
and percutaneous cyst drainage under ultrasound or CT 
guidance should be employed in infected liver cysts. The 
antibiotics administered should be capable of penetration 
into liver cysts, such as ciprofloxacin or amikacin. Cyst 
hemorrhage may present with similar findings to an 
infected liver. This is a rare complication, which is best 
diagnosed by MRI. 
Cysts in other organs
Cysts of the seminal vesicles, pancreas, and arachnoid 
membrane are present in 40% (of men), 5%, and 8% 
of patients respectively [56, 57]. Seminal vesicle cysts 
rarely result in infertility. Pancreatic cysts are almost 
always asymptomatic, with very rare instances of 
recurrent pancreatitis [58]. Arachnoid membrane cysts 
are often asymptomatic, but can increase the risk of 
subdural hematomas [59]. Spinal meningeal diverticula 
can occur with increased frequency and rarely present 
with intracranial hypotension due to cerebrospinal fluid 
leak [60].
Abdominal wall hernia
Compared to patients with renal failure due to other 
causes, ADPKD patients have a significantly higher 
incidence of abdominal wall hernia that appears to 
be due to the underlying defect in extracellular matrix 
production. A retrospective review compared ADPKD 
patients on dialysis with age- and sex-matched renal 
failure patients without ADPKD and with general surgical 
patients.  In this study, a hernia was present in 38 of 85 
(45%) ADPKD patients compared to seven of 85 (8%) 
patients with other forms of renal failure and three of 85 
(4%) general surgical controls (P < 0.001). There were 
significantly greater numbers of inguinal, incisional and 
para-umbilical hernias in patients with ADPKD compared 
with the other two groups [61].
Intracranial aneurysms 
Serious extra-renal manifestations of ADPKD include 
intracranial aneurysms (ICAs) and rupture of intracranial 
aneurysms (RICAs). ICAs are seen in approximately 
4-11.7% of ADPKD patients compared to 1-5% of the 
general population. ICAs are more common in those 
with a family history of this condition [62-64]. The risk 
of subarachnoid hemorrhage (SAH) is approximately 
five-fold higher in ADPKD patients compared to the 
general population [65].  ICAs are usually asymptomatic. 
Aneurysmal rupture carries a 35–55% risk of combined 
severe morbidity and mortality [66]. RICAs are 
responsible for 4-7% of deaths in patients with ADPKD 
and hemorrhage tends to occur at a younger age (mean 
age of 35-45 years) than in the general population [36, 
39]. Most patients have normal renal function and up 
to 29% have normal BP at the time of rupture. Because 
of family clustering, a family history of a ruptured ICA 
is an indication for screening imaging [67, 68]. Other 
indications for screening include previous aneurysm 
rupture, preparation for major elective surgery that is 
likely to be associated with hemodynamic instability and 
hypertension, high-risk occupations (e.g. airline pilots), 
and patient anxiety despite adequate information [69]. 
Magnetic resonance angiography (MRA) is currently 
the preferred screening procedure for ICA in ADPKD 
[70].  However, it is recommended that gadolinium-
based imaging be avoided, if possible, in patients with 
an estimated GFR less than 30 ml/min because of the 
newly recognized severe nephrogenic systemic fibrosis 
syndrome, which has been linked to gadolinium. 
Whether to expose patients with an estimated GFR 
of 30-60 ml/min to gadolinium or not is controversial. 
When an asymptomatic ICA is found, the advisability of 
intervention depends on cyst size, site, and morphology 
as well as history of SAH from another aneurysm, 
patient’s age and general health, and whether the 
Arab Journal of Nephrology and Transplantation
33
Autosomal dominant polycystic kidney disease
aneurysm is suitable for coiling or clipping [71]. The risk 
of new aneurysms development or existing aneurysm 
enlargement is very low in ADPKD patients with small 
(< 7 mm) asymptomatic aneurysms and moderate in those 
with history of rupture in a different site [72]. Therefore, 
conservative management is usually recommended for 
patients with small (< 7 mm) aneurysms, particularly in the 
anterior circulation. Semiannual or annual repeat imaging 
studies are appropriate initially, but reassessment at less 
frequent intervals might be sufficient once the stability 
of the aneurysm has been documented. Symptomatic 
aneurysms of any size and those 7-10 mm in diameter 
should be corrected surgically or by endovascular repair, 
since these lesions have a high risk of rupture (up to 
2% per year for larger aneurysms) [73]. Patients with 
aneurysms who are managed conservatively should be 
instructed to avoid uncontrolled hypertension, smoking, 
heavy alcohol consumption, stimulant medications, illicit 
drugs, and excessive straining. 
Cardiac manifestations
A significant correlation between LVMI and mean 
arterial pressure in adults with ADPKD has been 
observed. ADPKD children with hypertension also have 
an increased LVMI compared to normotensive ADPKD 
children [74]. An increase in LVMI may be detected 
earlier than an increase in renal volume in children 
with ADPKD and borderline hypertension, suggesting 
that close monitoring of cardiac status is indicated in 
these children [75]. Hypertension, particularly when 
associated with LVH, has emerged as the most frequent 
and treatable complication in ADPKD patients [76]. This 
is of particular relevance, since in the present era of renal 
replacement therapy cardiovascular complications are 
the most frequent cause of death in ADPKD [33].
Valvular abnormalities detected by echocardiography 
are more frequent in ADPKD patients compared to the 
general population. Mitral valve prolapse (MVP) is the 
most common disorder (26-31% vs. 2%) followed by 
aortic regurgitation (8%) [77, 78]. Although most patients 
are asymptomatic, the lesions may progress over time 
and become severe enough to require valve replacement 
[79].  
Pain
Acute or chronic pain is known as the most common 
complaint among ADPKD patients; approximately 60% 
of ADPKD patients experience abdominal and flank pain 
[20, 80, 81]. The most common etiologies of acute pain 
are cyst rupture, hemorrhagic or infected cysts, urinary 
tract infection and nephrolithiasis. While cyst infection 
clinically mimics pyelonephritis, the former presents with 
low-grade fever and more localized, non-positional flank 
pain [82]. Blood cultures are the most reliable diagnostic 
tests in identifying cyst infection [83]. The best imaging 
diagnostic method for infected cysts are contrast enhanced 
CT or MRI and scintigraphy with indium-111 labeling of 
leukocytes [84, 85]. Infected cysts should be treated with 
lipophilic agents such as clindamycin, ciprofloxacin, 
norfloxacin, and trimethoprim-sulfamethoxazole, for 
a course of six weeks. In ADPKD patients who have 
undergone treatment for urinary tract infection (UTI), the 
persistence of severe pain and more serious complications 
indicates perinephric abscess and may require surgical 
intervention [86]. 
Basic analgesic therapy with non-steroidal anti-
inflammatory drugs (NSAIDs) for 2-3 days might be 
helpful in ADPKD patients with renal colic [87-89]. 
Multiple studies have indicated no difference between 
the usage of NSAIDs and opioids in the treatment of 
colic due to renal stones. It has been shown that ESWL 
and nephrolithotomy may provide favorable results in 
symptomatic ADPKD patients with renal calculi [90, 
91]. 
Due to continuous cytogenesis and progressive kidney 
enlargement, most ADPKD patients will experience a dull, 
chronic flank discomfort. This pain might be due to renal 
capsule traction or related to asymmetric lumbosacral 
muscle hypertrophy [82]. Optional treatments consist 
of physical therapy measures (e.g. heating pads, ice 
massage), psychobehavioral modification techniques, 
and systemic analgesics. Physical interventions might 
also be beneficial such as transcutaneous electrical 
nerve stimulation (TENS), autonomic plexus blockade, 
neuromodulation by spinal cord stimulation, neuraxial 
opioids and local anesthetics, surgical decompression 
of kidney and liver cysts, partial hepatectomy and/
or nephrectomy [82, 92]. In one study of 15 ADPKD 
patients with uncontrolled abdominal pain and large 
cysts, cyst decompression using 99% ethanol resulted 
in remarkable pain relief. Considering the small size of 
this study population, more evaluation for this safe, cost 
effective therapy is needed [93]. On the other hand, a 
recent follow-up study of 12 pediatric patients showed 
promising results for laparoscopic renal denervation and 
nephropexy as a therapeutic option in severe chronic 
ADPKD-related pain [94].  
ADPKD in children
Although ADPKD is often considered an adult disease, 
early studies have described the presence of the disease in 
childhood and even in utero [95, 96].  Clinical findings in 
ADPKD children vary. However, hypertension and flank 
and/or low back pain are very common. These findings 
are significantly associated with larger kidneys and 
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increased cyst numbers [43, 86]. Polyuria and impaired 
urinary concentration are also correlated with larger 
renal volumes [97]. Similar to adults, liver cysts may be 
the most common extra-renal manifestation in ADPKD 
children [41]. A recent study of 85 ADPKD children and 
adolescents conducted at the University of Colorado 
Health Sciences Center showed a significant correlation 
between both systolic and diastolic BP and LVMI. The 
study population was categorized into three levels of 
BP; hypertensive (BP greater than the 95th percentile 
for gender, age, and height), borderline hypertensive 
(BP within 75-95th percentile), and normotensive (BP 
less than 75th percentile). Surprisingly, when compared 
to the normotensive group, children with borderline 
hypertension had significantly elevated LVMI [75]. Due 
to the significant association between larger kidneys and 
early progression to ESRD, it is imperative to explore 
the beneficial effects of reducing renal growth and LVMI 
through early intervention with RAAS blockers. 
Diagnosis 
The diagnosis of ADPKD usually relies on renal 
imaging. Characteristic findings include large kidneys 
and numerous cysts scattered throughout both kidneys. 
Ultrasonography (US) is the most commonly used 
imaging modality though in certain settings genetic 
counseling and mapping is required for a definitive 
diagnosis. 
Counseling should be offered to patients prior to 
testing [98]. Despite the absence of curative therapy, 
earlier confirmation of the diagnosis could have 
several beneficial effects. These include allowing 
appropriate family planning, instituting early treatment 
for hypertension to prevent LVH and cardiovascular 
complications and slow renal disease progression and 
selecting genetically unaffected family members for 
living related donor transplantation. On the other hand, 
early diagnosis in young individuals could be perceived 
to result in emotional and career consequences as well as 
removal of the choice to know. Until effective therapies 
are available, the decision of testing should be made 
in collaboration with well informed subjects and their 
families. Nevertheless, children at risk for ADPKD 
should be monitored as hypertension is frequently under-
diagnosed and inadequately treated. 
Renal US is widely used for pre-symptomatic screening 
of at risk individuals and for evaluation of potential 
living-related kidney donors from families with ADPKD. 
Pei et al have recently revised the US diagnostic criteria 
for ADPDK, as previously used criteria tended to 
under-diagnose the disease in PKD2 gene carriers [99]. 
They screened 577 and 371 at-risk individuals from 58 
PKD1 and 39 PKD2 families respectively with renal 
US, using molecular genotyping as the gold standard 
for disease assignment. The presence of three or more 
(unilateral or bilateral) renal cysts was found sufficient 
for establishing the diagnosis in individuals aged 15-39 
years. By contrast, more stringent criteria are required 
for the older age groups because of increasing prevalence 
of simple renal cysts. The presence of two or more cysts 
in each kidney was found sufficient for individuals aged 
40-59 years, and four or more cysts in each kidney is 
required for individuals ≥ 60 years. Conversely, fewer 
than two renal cysts in at-risk individuals aged ≥ 40 
years is sufficient to exclude the disease. The utility 
of US for disease exclusion may be limited in at-risk 
individuals who are younger than 30 years and have a 
negative or indeterminate scan. In these individuals, 
repeat ultrasound scanning every 6 to 12 months may be 
helpful to detect new cysts. However, if these individuals 
are being evaluated as potential living-related kidney 
donors, then molecular genetic testing is justified [99]. 
Because CT and MRI are more sensitive than US, the 
aforementioned sonographic criteria are not applicable to 
these modalities. 
In up to 25% of ADPKD cases there may be no family 
history of the disease. Such instances may occur when 
an affected parent has not been diagnosed or is suffering 
from a mild form of the disease.  In up to 5% of cases, 
the disease may be due to a new mutation. In such cases, 
bilateral renal enlargement and cysts or the presence of 
multiple bilateral cysts with hepatic cysts together with 
the absence of other manifestations suggesting a different 
renal cystic disease provide presumptive evidence for the 
diagnosis. See Table 2 for the differential diagnosis of 
ADPKD. 
In acquired renal cystic disease associated with 
longstanding renal insufficiency, the kidneys are initially 
small. With time they can enlarge and resemble those of 
ADPKD. Localized renal cystic disease, characterized 
by non-progressive cystic transformation of a portion 
of a kidney, should be differentiated from asymmetric 
presentations of ADPKD, segmental multicystic dysplasia, 
and cystic neoplasms. In rare cases, medullary sponge 
kidney, a disorder characterized by tubular dilatation of 
the collecting ducts confined to the medullary pyramids, 
can mimic the urographic appearance of ADPKD. The 
absence of family history of the disease and sparing the 
renal cortex on CT or MRI point to the right diagnosis. 
Genetic testing can be used when the imaging results 
are equivocal or when a definite diagnosis is required in 
a younger individual, such as a potential living related 
kidney donors. Genetic testing can be done by linkage or 
direct DNA sequence analysis. The choice of performing 
either linkage or sequence analysis largely depends upon 
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which technique is feasible and available. A combined 
approach using both modalities may be most effective. 
This was shown in a study in which genetic linkage and 
direct DNA analysis was performed in patients from 
families with and without history of disease. Among two 
prospective kidney donors with positive family history, 
the use of both linkage and DNA sequencing was required 
to definitively exclude the presence of ADPKD [100].
Therapy
Renin Angiotensin Aldosterone System (RAAS) 
blockade
RAAS activation has been demonstrated in ADPKD 
patients and therapy directed towards its inhibition has 
been shown to effectively reduce LVH and proteinuria 
[101]. These findings are very important because LVH is 
a major risk factor for systolic and diastolic dysfunction, 
cardiac arrhythmias, sudden death and ischemic heart 
disease. The degree of proteinuria has been also shown 
to be a predictor of renal disease progression in a variety 
of chronic renal diseases (e.g. diabetic nephropathy, 
glomerulonephritis) as well as in ADPKD [102-104].
In spite of that, studies have not demonstrated a reno-
protective effect of ACE inhibitors or angiotensin receptor 
blockers (ARB) in ADPKD. In the Modification of Diet 
in Renal Disease (MDRD) study, which was designed to 
assess the role of dietary protein and phosphorous intake 
and level of BP control on renal disease progression, 
200 of 840 subjects had ADPKD. Overall, there was no 
significant reduction in GFR decline in those treated with 
either the low-protein diet or low BP, and ACE inhibitors 
were used in approximately 40% [105]. This study, 
however, was not designed to randomly assign patients 
with regard to angiotensin blocking agents. Maschio et 
al performed a prospective, randomized, double-blind 
placebo-controlled study to assess the benefits of ACE 
inhibition on renal progression in non-diabetic kidney 
disease (including patients with ADPKD). There was a lack 
of therapeutic efficacy in 64 ADPKD patients followed 
for about 3 years. Ramipril was the ACE inhibitor used 
and there was a doubling of serum creatinine with equal 
frequency when compared to a placebo-controlled group. 
One of the limitations of the study was a reduced GFR 
at the onset of intervention (a mean creatinine clearance 
of 42 ml/min) in the study group [106]. Patients may 
Table 2:  Differential diagnosis of autosomal dominant polycystic kidney disease
Renal cystic disorder Prevalence  
and inheritance
Distinguishing clinical findings
Tuberous sclerosis  
complex (TSC)
1 in 10000,  
autosomal dominant 
Skin lesions (facial angiofibromas, periungual fibroma, hypomelanotic 
macules, Shagreen patch), retinal hamartomas, seizures, mental retardation, 
cortical tuber, subependymal giant cell astrocytoma, cardiac rhabdomyoma, 
lymphangioleiomyomatosis, renal angiomyolipoma. Contiguous deletion of 
PKD1 and TSC2 results in severe polycystic kidney disease in infancy or early 
childhood with ESRD typically occurring in the first two decades of life.
Autosomal recessive 
polycystic kidney disease 
(ARPKD)
1 in 20000,  
autosomal recessive 
Collecting duct ectasia and/or macrocystic changes, nephrolithiasis, hyperten-




1 in 50000,  
autosomal dominant
Retinal hemangiomas, clear cell carcinomas of the kidney, cerebellar and 
spinal hemangioblastomas, pheochromocytoma, endocrine pancreatic tumors, 
and/or epididymal cystadenoma
Medullary sponge kidney 1 in 5000,  
autosomal dominant
Tubular dilatation of the collecting ducts  confined to the medullary pyramids, 
medullary nephrocalcinosis,  “paint brush”  appearance of renal papillae on 
intravenous pyelogram
Orofaciodigital syndrome very rare,  
X-linked dominant
Lethal in affected male individuals, oral  anomalies (hyperplastic frenula, cleft 
tongue, cleft palate or lip, and malposed teeth), facial anomalies (broad nasal 
root with hypoplasia of nasal alae and malar bones), and digital anomalies
Acquired  
renal cystic disease
Common Chronic renal failure or ESRD particularly on renal replacement therapy with 
multiple renal cysts associated with normal-sized or small kidneys and absent 
extra-renal manifestations of ADPKD.
Localized 
renal cystic disease
Uncommon Multiple cysts of various sizes separated by normal or atrophic parenchyma 
involving one kidney. Rare under 30 years but incidence increases with age
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have had advanced disease that was not amenable to any 
treatment. In a 7-year prospective trial assessing both the 
level of BP control and the class of antihypertensive agent 
used, no advantage of an ACE inhibitor (enalapril) versus 
a calcium channel blocker (amlodipine) was found in 
reducing the rate of decline in glomerular filtration rate in 
ADPKD patients as estimated by the MDRD equation. A 
significantly better reversal of LVH was however shown 
with ACE inhibitor versus the calcium channel blocker 
as well as a BP of less than 120/80 mmHg as compared 
to 135-140/85-90 mmHg [107]. Importantly, all of these 
studies evaluated relatively small numbers of patients 
for short periods of time after kidney insufficiency was 
established [108]. 
Clinical data support the hypothesis that the RAAS is 
activated in individuals with ADPKD. Normalization 
of renal blood flow in hypertensive ADPKD individuals 
with ACE inhibitors or an ARB is not complete since these 
agents result in incomplete inhibition of the RAAS, as 
aldosterone and angiotensin II are generated via multiple 
pathways. There is information that over time aldosterone 
and angiotensin “breakthrough” occurs in a significant 
number of patients receiving ACE inhibitors. Moreover, 
patients who demonstrate this “breakthrough” appear to 
have a worse outcome [109].  It is for these reasons that 
the HALT PKD Study aims to determine the efficacy 
of aggressive RAAS blockade utilizing a combination 
of an ACE inhibitor plus an ARB or placebo in slowing 
renal function decline in ADPKD [110]. This prospective 
randomized double blind clinical trial is underway. It is 
being funded by the National Institute of  Health and is 
conducted at seven centers throughout the United States 
to recruit over a thousand individual with ADPKD, both 
early (study A: estimated GFR ≥ 60 ml/min) and late 
(study B: estimated GFR 26-59 ml/min). The hypothesis 
to be tested is that intensive blockade of the RAAS with 
combination ACE inhibitor and ARBs will delay the 
progression of renal disease independent of BP control in 
participants compared with ACE inhibitor monotherapy. 
Another hypothesis to be tested is that rigorous versus 
moderate BP control will be more effective in slowing 
progression of renal disease in early ADPKD. The ACE 
inhibitor lisinopril is prescribed for all patients in the 
study (both study A and B) along with either the ARB 
telmisartan or placebo in a randomized fashion. In study 
A, hypertensive ADPKD subjects with higher GFR are 
randomized to achieve standard (120-130/70-80 mmHg) 
versus rigorous BP control (95-110/60-75mmHg).  The 
primary end-point is the change in kidney volume 
measured by MRI whereas secondary outcomes include 
the rate of change in estimated GFR, change in renal 
blood flow and left ventricular mass using MRI, change 
in albuminuria, and PKD related symptoms. In study 
B, hypertensive ADPKD subjects with lower GFR are 
randomized to ACE inhibitor and placebo versus ACE 
inhibitor and ARB therapy with a standard BP goal (110-
130/≤80 mmHg). The primary outcome is the time to the 
composite endpoints of doubling of serum creatinine, 
ESRD, or death. The HALT PKD study will determine 
if the activation of the RAAS and hypertension play 
independent roles in structural progression of renal cysts 
in ADPKD. It will also test whether those interventions 
affect morbidity markers including left ventricular mass 
and proteinuria. This study will continue for 5 years, so 
the follow-up period can be adequate. 
Novel therapies
Advances in the understanding of the genetics, molecular 
biology and pathophysiology of ADPKD have enabled 
new potential approaches that will hopefully have an 
effect on the disease. Recent studies indicated that cyclic 
adenosine monophosphate (cAMP) plays a central role in 
cystic fluid accumulation, cystogenesis and proliferation 
of cells derived from polycystic kidneys [111-113]. 
Vasopressin, via V2 receptor (VPV2R), activates adenylyl 
cyclase and cAMP production in cysts originated from 
principal cells of the collecting duct. Recent studies 
on murine cystic models, examining the effect of a 
non-peptide vasopressin antagonist (OPC-31260) 
have been conducted. The results indicated prevention 
of the renal cAMP accumulation, inhibition of renal 
cystogenesis, decreased kidney weights, and decreased 
blood urea nitrogen (BUN) [114, 115]. Additional studies 
were conducted to evaluate the effects of Tolvaptan 
(OPC-41061), a more potent vasopressin V2 antagonist. 
Currently two multicenter studies utilizing Tolvaptan 
(an open-label study and a phase 3, placebo-controlled, 
double-blind study) are in progress. Since hepatocytes 
lack VPV2Rs, these agents exerted no effect on polycystic 
liver disease.  Increased water intake in rat PKD models 
for 10 weeks resulted in a protective effect on the 
development of the renal cystic disease, presumably due 
to vasopressin suppression [116]. Increased fluid intake, 
either by itself or together with the administration of V2 
receptor antagonists, may therefore prove to slow the rate 
of growth of polycystic kidneys in humans [117].
Detection of the somatostatin receptor, subtype 2 (ss2), 
in kidney and hepatocytes and its inhibitory effect 
on cAMP, suggests a potential effect of somatostatin 
on cyst fluid secretion and enlargement in ADPKD 
patients [118]. Somatostatin has been tested in humans 
using a long-acting octreotide compound that is given 
intramuscularly every month for 6 months. Substantial 
retardation in kidney growth defined as change in kidney 
volume measured by CT imaging was found during the 
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period of octreotide therapy as compared with placebo 
(2.2 ±3.7 versus 5.9 ±5.4% /year; P < 0.01).
Recent studies indicate that ADPKD patients have 
increased mammalian target of rapamycin kinase 
(mTOR) activity [119].  In renal cystic cells mTOR leads 
to abnormal cyst formation. Based on this hypothesis, 
several studies have been conducted to examine the 
effects of mTOR inhibitors. Rapamycin is an FDA-
approved specific inhibitor of mTOR. It has been 
shown that rapamycin in rodent models reduces cell 
proliferation, retards cyst expansion and protects renal 
function [120]. Further experimental and clinical studies 
(phase 2 clinical trial with sirolimus and everolimus) are 
in progress [121]. Other experimental drugs being tested 
on PKD are summarized in Table 3. 
Table 3: Summary of existing drugs and potential experimental agents in the treatment of polycystic kidney disease*
System Drug Mechanism Pysiological effects Trial results/status














NA in fibropolycystic liver disease
Water AVP suppression  cAMP  Cyst growth
 Kidney weight
 Renal function


















mTOR inhibitors  Cell proliferation
 Cyst volume
 Renal volume
Phase I and II clinical trials
MEK PD-098059 MEK inhibitor  Cell proliferation
Caspase IDN-8050 Pan-caspase inhibitor  Cyst volume
 Kidney size
Reduction in BUN (rat)






6 month clinical trial
AVP = arginine vasopressin; BUN = blood urea nitrogen; cAMP = cyclic adenosine monophosphate; ERK = extracellular signal- 
regulated kinase; ET = endothelin; F.F = filtration fraction; GFR = glomerular filtration rate; LVH = left ventricular hypertrophy; 
MAP = mean arterial pressure; MEK = mitogen extracellular kinase; mTOR = mammalian target of rapamycin; NA = data not 
available; PLC = phospholipase C; RAAS = renin-angiotensin-aldosterone system; RPF = renal plasma flow; V2= vasopressin 2; 
 indicates increase;  indicate decrease
* Reproduced with permission [42]




ADPKD patients who progress to ESRD require renal 
replacement therapy with options similar to other ESRD 
patients, including dialysis or renal transplantation. 
Peritoneal dialysis is assumed to result in poorer long-term 
technique survival because of various renal and non-renal 
aspects of ADPKD, including enlarged kidneys, abdominal 
wall complications, leaks, and intestinal perforation 
[122-125]. However a recent retrospective analysis 
comparing results of 56 consecutive ADPKD patients 
to 56 non-diabetic patients with bilateral small kidneys 
treated with peritoneal dialysis and followed up for over 
37 months showed no significant differences in terms 
of mortality, kidney transplantation-censored technique 
survival, median death-censored technique survival, the 
number of patients switched permanently to hemodialysis 
due to technique failure or the rate of peritonitis [126]. 
Other centers have found that peritoneal dialysis is well 
tolerated and results in no specific difficulties in patients 
with ADPKD requiring renal replacement therapy [127]. 
Although the outcomes are usually good, there are some 
issues in the renal transplant recipient that are specific 
for ADPKD, including potential need for nephrectomy 
and higher rate of complications; namely post-transplant 
erythrocytosis, symptomatic aneurysms, urinary tract 
infections, diverticulitis, and gastrointestinal disorders 
requiring surgery [128-130]. Some patients require 
unilateral or bilateral nephrectomy in order to better 
accommodate the allograft, or because of recurrent UTI, 
chronic pain, or chronic hematuria [131, 132].
Conclusion
Recent advances in the genetic and molecular basis of 
ADPKD have yielded exciting approaches towards 
treatment. In early disease, parameters of renal function 
remain normal despite progressive and irreversible 
enlargement of the kidneys with parenchymal distortion. 
It is therefore prudent, as suggested by the CRISP study 
[7], that the change in kidney volume, rather than renal 
function parameters, be used as a marker of response to 
new therapies. Findings from the ongoing HALT PKD 
study should settle the role of RAAS blockade in renal 
and cardiac outcomes for ADPKD. Current clinical trials 
investigating multiple therapeutic targets bring hope for 
treatments that may impede the progression of ADPKD. 
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